Abstract:
BACKGROUND:Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive levels of tumour necrosis factor (TNF) and resultant neurotoxicity. Etanercept, a potent biologic TNF antagonist, reduces microglial activation in experimental models and has been therapeutically effective in models of brain and neuronal injury. Perispinal administration of etanercept, previously reported to be beneficial for the treatment of Alzheimer's disease, may facilitate delivery of etanercept into the brain. OBJECTIVE:The objective of this report is to document the initial clinical response to perispinal etanercept in the first chronic stroke cohort so treated. METHODS:Three consecutive patients with stable and persistent chronic neurological deficits due to strokes that had failed to resolve despite previous treatment and rehabilitation were evaluated at an outpatient clinic. They were treated off-label with perispinal etanercept as part of the clinic's practice of medicine. RESULTS:All three patients had chronic hemiparesis, in addition to other stroke deficits. Their stroke distributions were right middle cerebral artery (MCA), brainstem (medulla) and left MCA. The two patients with MCA strokes had both received acute thrombolytic therapy. Each of the three patients was treated with an initial dose of perispinal etanercept 13, 35 and 36 months following their acute stroke, respectively. Significant clinical improvement following perispinal etanercept administration was observed in all patients. Onset of clinical response was evident within 10 minutes of perispinal injection in all patients. Improvements in hemiparesis, gait, hand function, hemi-sensory deficits, spatial perception, speech, cognition and behaviour were noted among the patients treated. Each patient received a second perispinal etanercept dose at 22-26 days after the first dose that was followed by additional clinical improvement. CONCLUSIONS:Open-label administration of perispinal etanercept resulted in rapid neurological improvement in three consecutive patients with chronic neurological dysfunction due to strokes occurring 13-36 months earlier. These results suggest that stroke may result in chronic TNF-mediated pathophysiology that may be amenable to therapeutic intervention long after the acute event. Randomized clinical trials of perispinal etanercept for selected patients with chronic neurological dysfunction following stroke are indicated.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Tobinick Edoi
10.2165/11588400-000000000-00000subject
Has Abstractpub_date
2011-02-01 00:00:00pages
145-55issue
2eissn
1172-7047issn
1179-1934pii
4journal_volume
25pub_type
杂志文章相关文献
CNS DRUGS文献大全abstract::This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418070-00004
更新日期:2004-01-01 00:00:00
abstract::The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed. The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-020-00721-9
更新日期:2020-07-01 00:00:00
abstract::Neuropathic pain is a persistent pain condition that develops secondary to nerve injury. The two most common types of peripheral neuropathic pain are post-herpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). Amitriptyline, nortriptyline, desipramine and imipramine are TCAs that have been shown to be effecti...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200822050-00005
更新日期:2008-01-01 00:00:00
abstract::Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418001-00005
更新日期:2004-01-01 00:00:00
abstract:BACKGROUND:Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE:The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose i...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-018-0501-0
更新日期:2018-04-01 00:00:00
abstract::Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0250-2
更新日期:2015-05-01 00:00:00
abstract::Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-012-0032-z
更新日期:2013-05-01 00:00:00
abstract::Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11202620-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0162-6
更新日期:2014-06-01 00:00:00
abstract::Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe immunosuppression such as those with advanced HIV infection (i.e. AIDS) or those who have undergone bone marrow or solid organ transplantation. Immunocompetent patients are affected very rarely. The infection of the CNS may affect ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216050-00003
更新日期:2002-01-01 00:00:00
abstract::Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11633910-000000000-00000
更新日期:2012-09-01 00:00:00
abstract::Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216110-00003
更新日期:2002-01-01 00:00:00
abstract:BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-017-0421-4
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling ol...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-019-00633-3
更新日期:2019-07-01 00:00:00
abstract::Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11530280-000000000-00000
更新日期:2010-02-01 00:00:00
abstract::All current antipsychotic drugs block dopamine (DA) receptors, but the nature of the DA dysfunction in schizophrenia has not been clear. However, consistent evidence now shows that presynaptic dopaminergic function is altered in schizophrenia, specifically in terms of increased DA synthesis capacity, baseline synaptic...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0177-z
更新日期:2014-07-01 00:00:00
abstract:INTRODUCTION:Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting. Intravenous valproic acid lends itself well to a continuous infusion as it exhibits a relatively short half-life. We evaluated the pharmacokinetics and clinical efficacy of continuous infusion valproic acid in hos...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-015-0304-5
更新日期:2016-01-01 00:00:00
abstract::At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620060-00005
更新日期:2006-01-01 00:00:00
abstract::Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-015-0307-2
更新日期:2016-02-01 00:00:00
abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923060-00006
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:When otherwise unexplained, syncope in patients with Alzheimer's disease may be attributed to bradycardia caused by cholinesterase inhibitors. We studied prospectively the clinical events and cardiovascular changes occurring during treatment with donepezil in patients with Alzheimer's disease. METHODS:Conse...
journal_title:CNS drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00023210-200620050-00005
更新日期:2006-01-01 00:00:00
abstract::The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200721120-00004
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11595060-000000000-00000
更新日期:2011-11-01 00:00:00
abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-020-00727-3
更新日期:2020-06-01 00:00:00
abstract::Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00702-y
更新日期:2020-04-01 00:00:00
abstract::The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Admi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0147-5
更新日期:2014-05-01 00:00:00
abstract:BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0102-x
更新日期:2013-11-01 00:00:00
abstract::Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0279-2
更新日期:2015-09-01 00:00:00
abstract::Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...
journal_title:CNS drugs
pub_type: 评论,杂志文章
doi:10.2165/00023210-200822030-00006
更新日期:2008-01-01 00:00:00
abstract::The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200620080-00004
更新日期:2006-01-01 00:00:00